Spero Therapeutics Inc (FRA:2HA)
€ 1.222 -0.032 (-2.55%) Market Cap: 65.12 Mil Enterprise Value: 12.44 Mil PE Ratio: 3.91 PB Ratio: 0.89 GF Score: 29/100

Q1 2021 Spero Therapeutics Inc Earnings Call Transcript

May 06, 2021 / 08:30PM GMT
Release Date Price: €10.5 (-7.08%)
Operator

Greetings, and welcome to Spero Therapeutics First Quarter 2021 Earnings Call. (Operator Instructions) As a reminder, this conference is being recorded.

I would now like to turn the conference over to your host, Ashley Robinson of Investor Relations.

Ashley R. Robinson
LifeSci Advisors, LLC - MD

Thanks, Joe, and thank you all for participating in today's conference call. Earlier today, Spero Therapeutics released financial results and provided a pipeline update for the first quarter of 2020. If you have not yet seen the press release, it is available on the Investors page of the Spero Therapeutics website.

Before we begin, I would like to remind you that some of the information contained in the news release and on this conference call contains forward-looking statements based on our current expectations, including statements about the initiation, timing and submission to the FDA of an NDA for tebipenem HBr and the potential approval of tebipenem HBr by the FDA; future commercialization, the potential number of patients who could be treated

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot